InvestSMART

Kazia Therapeutics Limited (ASX: KZA) - Announcements

DELISTED - Current share price for KZA : $0.080

ASX company news and announcements for Kazia Therapeutics Limited (KZA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Kazia Therapeutics Limited (KZA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Kazia Therapeutics Limited (KZA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Kazia Therapeutics Limited (KZA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Cleansing Notice - updated 11 Aug 2023 1:11PM $0.140 $0.080 fallen by 42.86%
- Cleansing Notice 11 Aug 2023 9:59AM $0.145 $0.080 fallen by 44.83%
- Application for quotation of securities - KZA 11 Aug 2023 9:56AM $0.145 $0.080 fallen by 44.83%
- Kazia announces change to Board of Directors 11 Aug 2023 8:25AM $0.145 $0.080 fallen by 44.83%
- Appointment of Dr John Friend as Managing Director 1 Aug 2023 1:32PM $0.140 $0.080 fallen by 42.86%
- Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2023 8:57AM $0.135 $0.080 fallen by 40.74%
- Notification regarding unquoted securities - KZA 19 Jul 2023 11:38AM $0.140 $0.080 fallen by 42.86%
- Change in substantial holding 17 Jul 2023 5:30PM $0.140 $0.080 fallen by 42.86%
- Cleansing Notice 14 Jul 2023 9:54AM $0.155 $0.080 fallen by 48.39%
- Appendix 2A 14 Jul 2023 9:48AM $0.155 $0.080 fallen by 48.39%
- Proposed issue of securities - KZA 14 Jul 2023 8:22AM $0.155 $0.080 fallen by 48.39%
- Notification of cessation of securities - KZA 13 Jul 2023 3:36PM $0.155 $0.080 fallen by 48.39%
- Change in substantial holding 11 Jul 2023 8:18AM $0.140 $0.080 fallen by 42.86%
- Paxalisib receives Fast Track Designation from US FDA 7 Jul 2023 9:16AM $0.170 $0.080 fallen by 52.94%
- Kazia Corporate Update and Corporate Presentation 26 Jun 2023 9:17AM $0.175 $0.080 fallen by 54.29%
- Launch of LUMOS2 Study 8 Jun 2023 8:23AM $0.170 $0.080 fallen by 52.94%
- Constitution 7 Jun 2023 2:05PM $0.170 $0.080 fallen by 52.94%
- Appointment of Non-executive Director 5 Jun 2023 8:55AM $0.165 $0.080 fallen by 51.52%
- Kazia CEO participates in White House Cancer Moonshot Forum 26 May 2023 8:35AM $0.175 $0.080 fallen by 54.29%
- Cancel - Notification of cessation of securities - KZA 25 May 2023 4:24PM $0.175 $0.080 fallen by 54.29%
- Quarterly Activities/Appendix 4C Cash Flow Report - updated 9 May 2023 4:33PM $0.190 $0.080 fallen by 57.89%
- Notification regarding unquoted securities - KZA 8 May 2023 1:38PM $0.185 $0.080 fallen by 56.76%
- Notification of cessation of securities - KZA 5 May 2023 10:04AM $0.185 $0.080 fallen by 56.76%
- Final Director's Interest Notice - Dr J Garner 2 May 2023 2:55PM $0.190 $0.080 fallen by 57.89%
- Executive Leadership changes - Dr John Friend appointed CEO 1 May 2023 8:15AM $0.188 $0.080 fallen by 57.33%

26 - 50 of 476 results

Page 2 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.